210 related articles for article (PubMed ID: 20807806)
1. Amplifying TLR-MyD88 signals within tumor-specific T cells enhances antitumor activity to suboptimal levels of weakly immunogenic tumor antigens.
Geng D; Zheng L; Srivastava R; Velasco-Gonzalez C; Riker A; Markovic SN; Davila E
Cancer Res; 2010 Oct; 70(19):7442-54. PubMed ID: 20807806
[TBL] [Abstract][Full Text] [Related]
2. Cross-talk between 4-1BB and TLR1-TLR2 Signaling in CD8+ T Cells Regulates TLR2's Costimulatory Effects.
Joseph AM; Srivastava R; Zabaleta J; Davila E
Cancer Immunol Res; 2016 Aug; 4(8):708-16. PubMed ID: 27267778
[TBL] [Abstract][Full Text] [Related]
3. Mycobacterium indicus pranii therapy induces tumor regression in MyD88- and TLR2-dependent manner.
Kumar P; Das G; Bhaskar S
BMC Res Notes; 2019 Oct; 12(1):648. PubMed ID: 31590685
[TBL] [Abstract][Full Text] [Related]
4. A Synthetic CD8α:MyD88 Coreceptor Enhances CD8
Kaczanowska S; Joseph AM; Guo J; Tsai AK; Lasola JJ; Younger K; Zhang Y; Gonzales CV; Davila E
Cancer Res; 2017 Dec; 77(24):7049-7058. PubMed ID: 29055013
[TBL] [Abstract][Full Text] [Related]
5. When Toll-like receptor and T-cell receptor signals collide: a mechanism for enhanced CD8 T-cell effector function.
Geng D; Zheng L; Srivastava R; Asprodites N; Velasco-Gonzalez C; Davila E
Blood; 2010 Nov; 116(18):3494-504. PubMed ID: 20696947
[TBL] [Abstract][Full Text] [Related]
6. Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity.
Asprodites N; Zheng L; Geng D; Velasco-Gonzalez C; Sanchez-Perez L; Davila E
FASEB J; 2008 Oct; 22(10):3628-37. PubMed ID: 18587008
[TBL] [Abstract][Full Text] [Related]
7. Deletion of MyD88 in T Cells Improves Antitumor Activity in Melanoma.
Bayer AL; Padilla-Rolon D; Smolgovsky S; Hinds PW; Alcaide P
Am J Pathol; 2024 Jun; 194(6):1007-1019. PubMed ID: 38442804
[TBL] [Abstract][Full Text] [Related]
8. A critical role for direct TLR2-MyD88 signaling in CD8 T-cell clonal expansion and memory formation following vaccinia viral infection.
Quigley M; Martinez J; Huang X; Yang Y
Blood; 2009 Mar; 113(10):2256-64. PubMed ID: 18948575
[TBL] [Abstract][Full Text] [Related]
9. Optimization of T-cell Receptor-Modified T Cells for Cancer Therapy.
Drakes DJ; Rafiq S; Purdon TJ; Lopez AV; Chandran SS; Klebanoff CA; Brentjens RJ
Cancer Immunol Res; 2020 Jun; 8(6):743-755. PubMed ID: 32209638
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of antitumor natural killer cell activation by orally administered Spirulina extract in mice.
Akao Y; Ebihara T; Masuda H; Saeki Y; Akazawa T; Hazeki K; Hazeki O; Matsumoto M; Seya T
Cancer Sci; 2009 Aug; 100(8):1494-501. PubMed ID: 19432881
[TBL] [Abstract][Full Text] [Related]
11. Impaired innate immunity in Tlr4(-/-) mice but preserved CD8+ T cell responses against Trypanosoma cruzi in Tlr4-, Tlr2-, Tlr9- or Myd88-deficient mice.
Oliveira AC; de Alencar BC; Tzelepis F; Klezewsky W; da Silva RN; Neves FS; Cavalcanti GS; Boscardin S; Nunes MP; Santiago MF; Nóbrega A; Rodrigues MM; Bellio M
PLoS Pathog; 2010 Apr; 6(4):e1000870. PubMed ID: 20442858
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.
Church SE; Jensen SM; Antony PA; Restifo NP; Fox BA
Eur J Immunol; 2014 Jan; 44(1):69-79. PubMed ID: 24114780
[TBL] [Abstract][Full Text] [Related]
13. Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.
Palmer DC; Balasubramaniam S; Hanada K; Wrzesinski C; Yu Z; Farid S; Theoret MR; Hwang LN; Klebanoff CA; Gattinoni L; Goldstein AL; Yang JC; Restifo NP
J Immunol; 2004 Dec; 173(12):7209-16. PubMed ID: 15585842
[TBL] [Abstract][Full Text] [Related]
14. A Critical Role of CD40 and CD70 Signaling in Conventional Type 1 Dendritic Cells in Expansion and Antitumor Efficacy of Adoptively Transferred Tumor-Specific T Cells.
Oba T; Hoki T; Yamauchi T; Keler T; Marsh HC; Cao X; Ito F
J Immunol; 2020 Oct; 205(7):1867-1877. PubMed ID: 32848036
[TBL] [Abstract][Full Text] [Related]
15. Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity.
Hartman ZC; Osada T; Glass O; Yang XY; Lei GJ; Lyerly HK; Clay TM
Cancer Res; 2010 Sep; 70(18):7209-20. PubMed ID: 20823152
[TBL] [Abstract][Full Text] [Related]
16. SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint.
Hajaj E; Eisenberg G; Klein S; Frankenburg S; Merims S; Ben David I; Eisenhaure T; Henrickson SE; Villani AC; Hacohen N; Abudi N; Abramovich R; Cohen JE; Peretz T; Veillette A; Lotem M
Elife; 2020 Mar; 9():. PubMed ID: 32122464
[TBL] [Abstract][Full Text] [Related]
17. T-cell receptor gene therapy of established tumors in a murine melanoma model.
Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
[TBL] [Abstract][Full Text] [Related]
18. Potent immunotherapy against well-established thymoma using adoptively transferred transgene IL-6-engineered dendritic cell-stimulated CD8+ T-cells with prolonged survival and enhanced cytotoxicity.
Kalyanasundaram Bhanumathy K; Zhang B; Xie Y; Xu A; Tan X; Xiang J
J Gene Med; 2015; 17(8-9):153-60. PubMed ID: 26212685
[TBL] [Abstract][Full Text] [Related]
19. TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity.
Geng D; Kaczanowska S; Tsai A; Younger K; Ochoa A; Rapoport AP; Ostrand-Rosenberg S; Davila E
Cancer Res; 2015 May; 75(10):1959-1971. PubMed ID: 25795705
[TBL] [Abstract][Full Text] [Related]
20. Costimulation through TLR2 Drives Polyfunctional CD8
Salerno F; Freen-van Heeren JJ; Guislain A; Nicolet BP; Wolkers MC
J Immunol; 2019 Feb; 202(3):714-723. PubMed ID: 30578304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
